Related wellness product · not a peptide
Injection and nasal programs, with first-month offers separated from recurring prices. NAD+ is a coenzyme, not a peptide.
Advertised starting price. The help center describes multi-month plans; exact initial charge, strength and supply are confirmed during consultation. No separate membership is advertised; shipping is advertised as included. If treatment is declined, the help center describes a refund less a nonrefundable consultation fee of unverified amount.
Advertised starting price. The help center describes multi-month plans; exact initial charge, strength and supply are confirmed during consultation. No separate membership is advertised; shipping is advertised as included. If treatment is declined, the help center describes a refund less a nonrefundable consultation fee of unverified amount.
Inspect the terms, then compare
Sorting compares displayed numbers only. Billing units, routes, supply periods and included services can differ. Featured placements above are separate.
First month advertised at $79; subsequent monthly price $149. Introductory pricing is attached to a three-month plan paid in full. Confirm the complete initial invoice. Provider review and shipping are included in the offer.
Wellness catalog lists $149 for 500 mg at 200 mg/mL. The reviewed catalog does not establish the exact replenishment interval for every prescription.
Monthly option: $173 first month, then $196. Visit, medication and shipping are advertised as included. A separate three-month option has different prices.
Monthly option: $217 first month, then $246. Visit, medication and shipping are advertised as included. A separate three-month option has different prices.
Monthly plan is $120 initially, then $135. A three-month alternative is advertised at $112 initially, then $127; its commitment differs.
No matching offers. Try another filter.
Biological roles for NAD+ do not establish that buying an injectable or nasal preparation improves longevity or fatigue. FDA has received adverse-event reports involving NAD+ injectable drugs and has warned compounders about unsuitable ingredients for sterile preparations. Those reports are not findings about the individual providers on this board.
Sources: FDA — ingredients for sterile compounding, FDA — compounding questions and answers
Follow the evidence
Checked October 8, 2026. Provider pages document advertised terms; they do not independently establish clinical outcomes.
NAD+ adverse-event reports and ingredient-quality concerns; not a finding about any listed provider.
Clinical and regulatory context. A compounded preparation is not FDA-approved.
Official public information; price and terms checked October 8, 2026.
Official public information; price and terms checked October 8, 2026.
Official public information; price and terms checked October 8, 2026.
Official public information; price and terms checked October 8, 2026.
Official public information; price and terms checked October 8, 2026.
Official public information; price and terms checked October 8, 2026.